Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib Combined With Salvage Chemotherapy in R/R AML
NCT02626338Phase 2Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Feb 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of crenolanib in acute myeloid leukemia (AML) (3 arms), sponsored by AROG Pharmaceuticals, Inc. Primary endpoint: Clinical Response to Crenolanib With Standard Salvage Chemotherapy at 1 year. Started Feb 2016; status: completed.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02626338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626338.